University of Exeter’s Neurodegeneration Imaging Group
Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer
The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care
Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS
If approved, this treatment would offer a new option for the nearly one million Americans living with MS
Roche and Dualitas Therapeutics announce research collaboration worth up to $1bn
The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases
Roche’s Enspryng gets FDA Priority Review for autoimmune disease with no approved treatments
MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain
Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment
This is the first and only at-home subcutaneous treatment option for this disease
Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer
Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years
Roche and Nurix Therapeutics to partner in $2.3bn deal
The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology
AL-S Pharma release new data from AP-101 phase 2 trial for ALS
ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord
Sumitomo Pharma’s stem cell therapy for Parkinson’s given limited approval in Japan
The company has been given manufacturing and marketing authorisation for the therapy
Annovis partners with NeuroRPM on new AI platform to track Parkinson’s symptoms
The platform will passively collect data to understand treatment responses in everyday life
Roche opens new Swiss Institute of Human Biology research facility
The new building is part of a 1.5bn euro site investment
Roche’s Columvi improves survival in large B-cell lymphoma
Approximately 160,000 people are diagnosed with this aggressive form of cancer each year